We are a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of inflammatory diseases and cancer.
Quote | Fortress Biotech Inc. (NASDAQ:FBIO)
Last: | $1.76 |
---|---|
Change Percent: | 0.0% |
Open: | $1.69 |
Close: | $1.76 |
High: | $1.85 |
Low: | $1.67 |
Volume: | 188,762 |
Last Trade Date Time: | 07/03/2024 03:00:00 am |
News | Fortress Biotech Inc. (NASDAQ:FBIO)
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional in...
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has completed the resubmission of its Biologics License Application (“BLA”) t...
Message Board Posts | Fortress Biotech Inc. (NASDAQ:FBIO)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $FBIO News Article - Checkpoint Therapeutics Announces $6.1 Million Registered Direct O | whytestocks | investorshangout | 03/31/2023 5:40:56 PM |
whytestocks: $FBIO News Article - Journey Medical Corporation Reports Full-Year 2022 Financial Resul | whytestocks | investorshangout | 03/29/2023 8:26:10 PM |
whytestocks: $FBIO News Article - Journey Medical Corporation to Participate in the 35th Annual ROTH | whytestocks | investorshangout | 03/07/2023 6:35:47 PM |
Has $FBIO gotten a NASDAQ warning letter yet? | Spicknspan | investorshub | 02/28/2023 12:20:02 AM |
whytestocks: $FBIO News Article - Helocyte, Inc. Announces Positive Data from Stem Cell Transplant D | whytestocks | investorshangout | 02/16/2023 7:40:48 PM |
News, Short Squeeze, Breakout and More Instantly...
Fortress Biotech Inc. Company Name:
FBIO Stock Symbol:
NASDAQ Market:
Fortress Biotech Inc. Website:
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single healthcare-dedicated institutional in...
WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has completed the resubmission of its Biologics License Application (“BLA”) t...
WALTHAM, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has reached alignment with the Food and Drug Administration (“FDA”) on its bi...